# To Evaluate the Safety, Tolerability, and Pharmacokinetics Profile in Healthy Chinese Volunteers of TG-2349

> **NCT03610867** · PHASE1 · COMPLETED · sponsor: **Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.** · enrollment: 64 (actual)

## Conditions studied

- Healthy Chinese Volunteers

## Interventions

- **DRUG:** Furaprevir capsule (SAD)
- **DRUG:** Furaprevir capsule (MAD)
- **DRUG:** Placebo (SAD)
- **DRUG:** Placebo (MAD)

## Key facts

- **NCT ID:** NCT03610867
- **Lead sponsor:** Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-27
- **Primary completion:** 2017-08-31
- **Final completion:** 2017-08-31
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2018-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03610867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03610867, "To Evaluate the Safety, Tolerability, and Pharmacokinetics Profile in Healthy Chinese Volunteers of TG-2349". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03610867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*